Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena

被引:8
作者
Samaddar, Arghadip [1 ]
Grover, Malika [1 ]
Nag, Vijaya Lakshmi [1 ]
机构
[1] All India Inst Med Sci, Dept Microbiol, Jodhpur, Rajasthan, India
关键词
coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2; antiviral; anti-inflammatory; drug repurposing; pathophysiology; immunotherapy; CONVALESCENT PLASMA THERAPY; CORONAVIRUS DISEASE 2019; NUCLEOCAPSID PROTEINS; SARS; INFECTION; REPLICATION; SARS-COV-2; MODEL; INHIBITOR; MORTALITY;
D O I
10.3389/fphar.2020.585888
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Coronavirus disease 2019 (COVID-19), an acute onset pneumonia caused by a novelBetacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in the Wuhan City of China in December 2019 and evolved into a global pandemic. To date, there are no proven drugs or vaccines against this virus. Hence, the situation demands an urgent need to explore all potential therapeutic strategies that can be made available to prevent the disease progression and improve patient outcomes. In absence of clinically proven treatment guidelines, several repurposed drugs and investigational agents are currently being evaluated in clinical trials for their probable benefits in the treatment of COVID-19. These include antivirals (remdesivir, lopinavir/ritonavir, umifenovir, and favipiravir), interferon, antimalarials (chloroquine/hydroxychloroquine), antiparasitic drugs (ivermectin and nitazoxanide), biologics (monoclonal antibodies and interleukin receptor antagonist), cellular therapies (mesenchymal stem cells and natural killer cells), convalescent plasma, and cytokine adsorber. Though several observational studies have claimed many of these agents to be effective based on theirin vitroactivities and extrapolated evidence from SARS and Middle East respiratory syndrome (MERS) epidemics, the currently available data remains inconclusive because of ill-defined patient selection criteria, small sample size, lack of concurrent controls, and use of intermediary outcomes instead of patient-relevant outcomes. Moreover, there is a need to clearly define the patient populations who warrant therapy and also the timing of initiation of treatment. Understanding the disease pathology responsible for the clinical manifestations of COVID-19 is imperative to identify the potential targets for drug development. This review explains the pathophysiology of COVID-19 and summarizes the potential treatment candidates, which can provide guidance in developing effective therapeutic strategies.
引用
收藏
页数:19
相关论文
共 110 条
  • [1] The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management
    Abou-Ismail, Mouhamed Yazan
    Diamond, Akiva
    Kapoor, Sargam
    Arafah, Yasmin
    Nayak, Lalitha
    [J]. THROMBOSIS RESEARCH, 2020, 194 : 101 - 115
  • [2] Antimicrobial Activity of Mesenchymal Stem Cells: Current Status and New Perspectives of Antimicrobial Peptide-Based Therapies
    Alcayaga-Miranda, Francisca
    Cuenca, Jimena
    Khoury, Maroun
    [J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [3] [Anonymous], 2020, medRxiv, DOI [DOI 10.1101/2020.03.30.20047365, 10.1101/2020.03.30.20047365]
  • [4] [Anonymous], 2015, Methods Mol Biol, DOI [DOI 10.1007/978-1-4939-2438-71, 10.1007/978-1-4939-24387_1, DOI 10.1007/978-1-4939-2438-7_1]
  • [5] Umbilical Cord as Prospective Source for Mesenchymal Stem Cell-Based Therapy
    Arutyunyan, Irina
    Elchaninov, Andrey
    Makarov, Andrey
    Fatkhudinov, Timur
    [J]. STEM CELLS INTERNATIONAL, 2016, 2016
  • [6] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response
    Astuti, Indwiani
    Ysrafil
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (04) : 407 - 412
  • [7] Atluri S, 2020, PAIN PHYSICIAN, V23, pE71
  • [8] Immunosenescence: emerging challenges for an ageing population
    Aw, Danielle
    Silva, Alberto B.
    Palmer, Donald B.
    [J]. IMMUNOLOGY, 2007, 120 (04) : 435 - 446
  • [9] MSC Based Therapies-New Perspectives for the Injured Lung
    Behnke, Judith
    Kremer, Sarah
    Shahzad, Tayyab
    Chao, Cho-Ming
    Boettcher-Friebertshaeuser, Eva
    Morty, Rory E.
    Bellusci, Saverio
    Ehrhardt, Harald
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (03)
  • [10] The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study
    Bellingan, Geoff
    Maksimow, Mikael
    Howell, David C.
    Stotz, Martin
    Beale, Richard
    Beatty, Monika
    Walsh, Timothy
    Binning, Alexander
    Davidson, Alan
    Kuper, Martin
    Shah, Sanjoy
    Cooper, Jackie
    Waris, Matti
    Yegutkin, Gennady G.
    Jalkanen, Juho
    Salmi, Marko
    Piippo, Ilse
    Jalkanen, Markku
    Montgomery, Hugh
    Jalkanen, Sirpa
    [J]. LANCET RESPIRATORY MEDICINE, 2014, 2 (02) : 98 - 107